SOLUTION

Life Sciences

Our Solutions
We support CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.

With our AI platform, we provide CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.

Aiosyn’s algorithms can be used to accelerate the development of biomarker-based therapeutic and patient stratification strategies

Selection of AI solutions
Lymphocyte detection
Detection of lymphocytes in immunostaining CD3, CD8, FoxP3, etc.
Ki-67 quantification
Detection of tumor cell growth in Ki-67 immunostaining.
Mitotic figure counting
Detection of mitotic figures in H&E sections.
Workflow
AI brings speed and accuracy

Our technology harnesses a powerful form of machine learning called “neural networks” (or deep learning) to identify abnormal tissue patterns such as cancer. Artificial intelligence has shown to do this with unprecedented accuracy and speed. For quantifying patterns and cells of interest, AI offers consistent quality, repeatability, and speed.

Contact us

Experience our AI-powered pathology algorithms

Contact with our team to experience our AI-powered pathology algorithms can help you with pathology workflow, clinical diagnostics and/or drug development programs.